FDA Approves Generic Eribulin Mesylate Injection for Cancer Treatment

The U.S. FDA has granted approval for Natco Pharma Limited's generic version of Eribulin Mesylate Injection. This medication is indicated for adult patients with metastatic breast cancer and certain types of liposarcoma who have undergone previous chemotherapy. The approval expands access to a treatment option for these cancer conditions.